Novo Nordisk (NOVOB80) Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details

NOVOB80 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 56.8% below our estimate of its fair value

Earnings grew by 16.6% over the past year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Has a high level of debt

Dividend of 3.91% is not well covered by free cash flows

Volatile share price over the past 3 months compared to the TH market

NOVOB80 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Novo Nordisk A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share Price	DKK 1.49
52 Week High	DKK 2.70
52 Week Low	DKK 1.12
Beta	0.35
1 Month Change	22.13%
3 Month Change	-3.87%
1 Year Change	-34.07%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-62.37%

Recent updates

Shareholder Returns

	NOVOB80	TH Pharmaceuticals	TH Market
7D	1.4%	-1.2%	2.1%
1Y	-34.1%	11.9%	29.9%

Return vs Industry: NOVOB80 underperformed the TH Pharmaceuticals industry which returned 11.9% over the past year.

Return vs Market: NOVOB80 underperformed the TH Market which returned 29.9% over the past year.

Price Volatility

Is NOVOB80's price volatile compared to industry and market?
NOVOB80 volatility
NOVOB80 Average Weekly Movement	7.9%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	5.0%
10% most volatile stocks in TH Market	10.0%
10% least volatile stocks in TH Market	2.6%

Stable Share Price: NOVOB80's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: NOVOB80's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TH stocks.

About the Company

Founded	Employees	CEO	Website
1923	67,900	Maziar Doustdar	www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVOB80 fundamental statistics
Market cap	฿6.71t
Earnings (TTM)	฿617.26b
Revenue (TTM)	฿1.66t

10.9x

P/E Ratio

4.0x

P/S Ratio

Is NOVOB80 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVOB80 income statement (TTM)
Revenue	DKK 327.80b
Cost of Revenue	DKK 55.09b
Gross Profit	DKK 272.72b
Other Expenses	DKK 150.76b
Earnings	DKK 121.96b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 05, 2026

Earnings per share (EPS)	27.51
Gross Margin	83.20%
Net Profit Margin	37.20%
Debt/Equity Ratio	67.7%

How did NOVOB80 perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

43%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/15 11:32
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 57 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Gerhard Schwarz	Baader Helvea Equity Research
José Romero Herrero	Banco Santander

Novo Nordisk (NOVOB80) Stock Overview

Rewards

Risk Analysis

Novo Nordisk A/S Competitors

Mega Lifesciences

AstraZeneca

Novartis

Merck

Price History & Performance

Recent News & Updates

Novo Nordisk Presents Wegovy Pill Clinical Trial Results and Product Updates

Novo Nordisk A/S Demonstrates Wegovy Delivers Substantial Weight Loss and Health Benefits for Women Across All Menopause Stages

Novo Nordisk A/S Demonstrates Higher Dose Wegovy Achieves Nearly 28% Weight Loss in Early Responders

Novo Nordisk Announces Positive Topline Results from Pioneer Teens Trial of Oral Semaglutide for Type 2 Diabetes in Children and Adolescents

Novo Nordisk Demonstrates Wegovy Pill At Obesity Medicine Association Conference

Novo Nordisk Announces Etavopivat Meets Co-Primary Endpoints in Phase 3 Hibiscus Trial for Sickle Cell Disease

Recent updates

Novo Nordisk Presents Wegovy Pill Clinical Trial Results and Product Updates

Novo Nordisk A/S Demonstrates Wegovy Delivers Substantial Weight Loss and Health Benefits for Women Across All Menopause Stages

Novo Nordisk A/S Demonstrates Higher Dose Wegovy Achieves Nearly 28% Weight Loss in Early Responders

Novo Nordisk Announces Positive Topline Results from Pioneer Teens Trial of Oral Semaglutide for Type 2 Diabetes in Children and Adolescents

Novo Nordisk Demonstrates Wegovy Pill At Obesity Medicine Association Conference

Novo Nordisk Announces Etavopivat Meets Co-Primary Endpoints in Phase 3 Hibiscus Trial for Sickle Cell Disease

Novo Nordisk A/S Receives Ema Approval for Controlled-Temperature Delivery of Wegovy Injection in Europe

Novo Nordisk A/S Announces Approval Of Awiqli Injection In The US

Novo Nordisk Announces FDA Approval of Awiqli Once-Weekly Basal Insulin for Adults with Type 2 Diabetes

Novo Nordisk A/S and The United Laboratories International Holdings Limited Announce Phase 2 Results For UBT251 In Chinese Patients With Type 2 Diabetes

Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With Oral Obesity Drug Candidate LX9851

Novo Nordisk A/S Announces Wegovy Hd (Semaglutide 7.2 Mg) Approval in Us

Novo Nordisk A/S Announces Changes of Employee Representatives to the Board of Directors

The United Laboratories International Holdings Limited and Novo Nordisk A/S Announces Topline Results from A Chinese Phase 2 Trial of UBT251

Novo Nordisk's Wegovy Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral Glp-1S in Obesity

The European Commission Approves More Effective Dose of Injectable Wegovy® for Adults with Obesity; Clinical Study Showed People Lost About 21% of Their Body Weight on Average

Novo Nordisk A/S Proposes Final Dividend for Each Novo Nordisk A and B Share for the Year 2025

Novo Nordisk A/S Announces Headline Results from REIMAGINE 2

Novo Nordisk A/S Announces Change in Employee Representative on Board of Directors, Effective January 31, 2026

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

LifeMD, Inc. Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy®? Pill

Novo Nordisk's Wegovy Pill, the First and Only Oral Glp-1 for Weight Loss in Adults, Now Broadly Available Across America

Novo Nordisk A/S Announces More Efficacious Dose of Wegovy®? Recommends by the European Medicines Agency

Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Akero Therapeutics, Inc. (NasdaqGS:AKRO).

Novo Nordisk Presents New Topline Results from Their Evoke and Evoke+ Phase 3 Trials of Semaglutide

Novo Nordisk Phase 2 Trial with Amycretin Reports Significant Weight Loss and HbA1c Reduction in Type 2 Diabetes

Novo Nordisk Announces Top-Line Results from the 2-Year Primary Analysis of Evoke and Evoke+ Phase 3 Trials in Early-Stage symptomatic Alzheimer's Disease

Novo Nordisk A/S to Report Q1, 2026 Results on Mar 26, 2026

Novo Nordisk A/S, Annual General Meeting, Mar 26, 2026

Novo Nordisk A/S Approves Board Members

Novo Nordisk Presents New Findings from the Step Up Phase 3B Trial

Novo Nordisk A/S Revises Earnings Guidance for the Year 2025

Pfizer Inc. Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk A/S

Pfizer Inc. Files Lawsuit Against Metsera, Inc. and Novo Nordisk, S.A. for Breach of Merger Agreement

Novo Nordisk A/S (CPSE:NOVO B) submitted an unsolicited proposal to acquire Metsera, Inc. (NasdaqGS:MTSR) ) for approximately $6 billion.

Novo Nordisk A/S Announces Not to Stand Re-Election of Directors

Novo Nordisk A/S Receives Exclusive Global Rights to Develop and Commercialise Zaltenibart in All Indications

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Akero Therapeutics, Inc. (NasdaqGS:AKRO) for approximately $4.4 billion.

Novo Nordisk Resubmits Awiqli®? to the FDA with Potential to Be the First Once-Weekly Insulin Icodec Treatment for Adults with Type 2 Diabetes

Novo Nordisk A/S Announces Results from the REACH Real-World Study

Novo Nordisk Presents Phase 3 Data for Next-Generation Amylin Amylin Cagrilintide, Leading to Advance into Dedicated Clinical Programme

Eu Approval Makes Novo Nordisk’S Oral Semaglutide the First and Only Oral Glp-1 Ra to Reduce Cardiovascular Death, Heart Attack and Stroke

Novo Nordisk Presents Data from the Steel Real-World Study of Evidence Grows from actual Patient Experiences at European Society of Cardiology Congress 2025

Novo Nordisk to Present Wegovy and Ozempic Data Showing Life-Saving Cardiovascular Benefits for People Living with Obesity and Type 2 Diabetes At the European Society of Cardiology Congress 2025

Health Canada Approves Ozempic to Reduce the Risk of Sustainable eGFR Decline, End-Stage Kidney Disease, and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease

US Food and Drug Administration Approves Novo Nordisk's Wegovy

Prothena Announces Novo Nordisk Will Advance Coramitug (Formerly Prx004) into Phase 3 Development for Attr Amyloidosis with Cardiomyopathy

Novo Nordisk Announces Chief Executive Officer Changes, Effective 7 August 2025

Novo Nordisk Continues Efforts to Support Patient Access to Authentic, FDA Approved Wegovy and Priority Patient Safety

Novo Nordisk Presents Results from the Phase 3b Step Up Trial in People with Obesity Without Diabetes

Novo Nordisk Presents Results from the Phase 3B FRONTIER5 Trial

Novo Nordisk to Advance Subcutaneous and Oral Amycretin for Weight Management into Phase 3 Clinical Development

Novo Nordisk to Present Array of New Portfolio Data Including Studies with Semaglutide and CagriSema, Expanding Evidence in Obesity and Diabetes Care at ADA 2025

Novo Nordisk A/S Announces Lars Fruergaard Jørgensen to Step Down as CEO

Novo Nordisk A/S to Report Fiscal Year 2025 Results on Feb 04, 2026

Ebn Sina Medical Co Announces Availability of Wegovy (Semaglutide 2.4Mg) in Qatar

Novo Nordisk Expands Patient Access to Authentic, FDA-Appoints Wegovy Via Collaborations with Multiple Telehealth Organizations

Parker Waichman LLP Files a Lawsuit Against Novo Nordisk

Novo Nordisk Announces Changes in Executive Management, as of 3 April 2025

Novo Nordisk A/S Announces Rybelsus® (Oral Semaglutide 14 mg) Demonstrates Superior Reduction in Cardiovascular Events in the SOUL Trial at ACC 2025

Novo Nordisk A/S Presents Full Results from STRIDE

Novo Nordisk Expands Wegovy $499-Per-Month Offering to Additional Cash-Paying Patients Via the Wegovy Savings Offer

Novo Nordisk A/S Announces Headline Results from Redefine 2, A Phase 3 Trial in the Global Redefine Programme